Status:
TERMINATED
A Phase II, Placebo-controlled Trial Evaluating the Efficacy of Antroquinonol in Patients With Atopic Dermatitis
Lead Sponsor:
Chung Shan Medical University
Collaborating Sponsors:
Golden Biotechnology Corporation
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
20-65 years
Phase:
PHASE2
Brief Summary
Primary Objective: To evaluate the activity of Antroquinonol in patients with atopic dermatitis. Secondary Objective: To assess the mechanism and cytokines change of Antroquinonol in patients with ...
Detailed Description
This is a Phase II, three-arms, double-blind, dosing-ranging, placebo-controlled trial evaluating the efficacy of Antroquinonol in patients with atopic dermatitis. The study is conducted in compliance...
Eligibility Criteria
Inclusion
- Patients between the ages of 20 and 65 years who had moderate-to-severe atopic dermatitis (using the Hanifin and Rajka Diagnostic Criteria)
- Patients with body weight ≥ 25 kg and ≤ 120 kg, signing informed consent
- To be eligible to participate, patients were required to have
- a score of at least 5 on the Eczema Area and Severity Index (EASI), which ranges from 0 to 72, with higher scores indicating worse disease severity;
- a score for pruritus of at least 30 mm on a visual-analogue scale, which ranges from 0 (no itch) to 100 mm (worst itch imaginable);
- a score of at least 2 on the static Investigator's Global Assessment (sIGA), which ranges from 0 (clear) to 4 ( severe disease).
- BSA affected or PSAI ≥ 5%
Exclusion
- Patients meeting any of the following criteria must not be enrolled in the study:
- Patients with active dermatologic diseases concomitant with atopic dermatitis.
- Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study
- Subjects with defective epidermal barrier(e.g Netherton's syndrome)
- Any subject who is immunocompromised or has a history of malignant disease. This information will be gathered verbally from the patient while taking a medical history from the patient, and will not involve further testing such as an HIV test.
- Subjects with a history of psychiatric disease or history of alcohol or drug abuse that would interfere with the ability to comply with the study protocol
- Any noticeable breaks or cracks in the skin on either arm, including severely excoriated skin or skin with open or weeping wounds suggestive of an active infection or increased susceptibility to infection.
- Ongoing participation in another investigational trial
- Use of any oral or topical antibiotic for up to four weeks prior to the Treatment visit or active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy
- Use of any systemic immunosuppressive therapy (e.g. CsA, MTX, etc.) within four weeks of the Treatment visit.
- Participant who has a condition or is in a situation that, in the investigator's opinion, may put the patient at significant risk, or may significantly interfere with the patient's participation in the study.
- Subjects with prosthetic heart valves, pacemakers, intravascular catheters, or other foreign or prosthetic devices.
- History of food or drug-related severe anaphylactoid or anaphylactic reaction(s)
- Pregnancy or breastfeeding
- History or presence of epilepsy, significant neurological disorders, cerebrovascular attack or ischemia
- History or presence of myocardial infarction or cardiac arrhythmia under drug therapy
- Patients who are unable to complete questionnaires on paper.
- Clinically significant laboratory abnormalities.
- History of malignancy of any organ system, treated or untreated.
Key Trial Info
Start Date :
July 27 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 25 2019
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT04110873
Start Date
July 27 2018
End Date
June 25 2019
Last Update
October 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chung Shan Medical University Hospital
Taichung, Taiwan, 402